Corpus Intelligence IC Memo — MARYLAND GENERAL HOSPITAL 2026-04-26 09:39 UTC
IC Memo — MARYLAND GENERAL HOSPITAL
Investment Committee Memorandum | MD | 201 beds | Grade C | EBITDA uplift $17.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MARYLAND GENERAL HOSPITAL

CCN 210038 | BALTIMORE CITY, MD | 201 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MARYLAND GENERAL HOSPITAL is a 201-bed under-performing / distressed in BALTIMORE CITY, MD with $231.7M in net patient revenue and a -16.0% operating margin. The hospital serves a payer mix of 27.1% Medicare, 6.6% Medicaid, and 66.3% commercial.

Thesis: Undervalued. Our ML models identify $17.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -16.0% to -8.7% (+736bps).

Net Revenue HCRIS$231.7M
Current EBITDA COMPUTED$-37.1M
Operating Margin COMPUTED-16.0%
Occupancy HCRIS50.5%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS85.5%
Distress Probability ML55.2%

2. Market Context & Competitive Position

59
MD Hospitals
-8.3%
State Median Margin
32
Comparable Hospitals

MD has 59 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of -16.0% places it below the state median. Among 32 size-comparable peers (100-402 beds), the median margin is -7.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (100-402), prioritizing same-state peers. 32 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MARYLAND GENERAL HOSPITAL (Target)MD201$231.7M-16.0%
ANNE ARUNDEL MEDICAL CENTER INMD379$616.6M-3.3%
MERCY MEDICAL CENTERMD173$561.3M-3.3%
MEDSTAR FRANKLIN SQUARE MEDICAMD354$537.6M-5.7%
HOLY CROSS HOSPITALMD399$516.0M-16.7%
ST. AGNES HOSPITALMD183$506.7M-12.2%
TIDALHEALTH PENINSULA REGIONALMD230$493.4M0.8%
AHC SHADY GROVE MEDICAL CENTERMD381$446.5M-3.8%
BALTIMORE WASHINGTON MEDICAL CMD314$440.2M-7.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $17.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.9M+210bp18mo
Cost to Collect4.5%2.5%$4.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.8M+122bp9mo
Clean Claim Rate88.0%96.0%$148K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.9M
Cost to Collect
$4.6M
Denial Rate Reduction
$4.6M
A/R Days Reduction
$2.8M
Clean Claim Rate
$148K
Total EBITDA Uplift$17.1M
Current EBITDA$-37.1M
+ RCM Uplift+$17.1M
Pro Forma EBITDA$-20.1M
Current Margin-16.0%
Pro Forma Margin-8.7%
WC Released (1x)$8.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-57.1M$-74.4M0.00x-100.0%
Base (11x exit)10.0x11.0x$-57.1M$-100.4M0.00x-100.0%
Bull Case9.0x11.0x$-51.4M$-62.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-51.4M$-83.5M0.00x-100.0%
Bear Case11.0x10.0x$-62.8M$-141.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-62.8M$-175.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 55.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 32 hospitals with 100-402 beds
  • Same-state prioritization (n=33)
  • Comp margins: P25=-12.2% / P50=-7.9% / P75=-3.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.